Netflix Inc (NASDAQ:NFLX, XETRA:NFC) reported first quarter financial results that topped Wall Street expectations, with stronger-than-anticipated revenue and earnings driven by membership growth, pricing adjustments, and expanding advertising income.
However, weak second quarter guidance saw the streaming platform's shares fall 9% afterhours. It guided revenue of $12.57 billion, which fell short of the $12.63 billion expected.
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies.
The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether multiple peptide-related bulk drug substances should be considered for possible inclusion on the 503A bulks list.
QVC Group (NASDAQ:QVCGA) has disclosed plans to seek Chapter 11 bankruptcy protection as part of a broader effort to restructure its debt of about $5 billion while continuing normal operations, rather than shutting down.
Shares of QVC fell more than 66% on the news.
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition.
Investors weighed near-term earnings strength against dilution from the company’s roughly $23 billion acquisition of Exact Sciences.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Thursday that preclinical research on its experimental intranasal therapy showed potential to reduce brain inflammation and improve cognitive function linked to Long COVID, according to a study published on bioRxiv.
The study evaluated foralumab, a fully human anti-CD3 monoclonal antibody administered through the nose, in a mouse model designed to mimic neurological symptoms of Long COVID without direct viral infection of the brain.
Shares in Sovereign Metals Ltd (ASX:SVM, OTCQX:SVMLF, AIM:SVML, FRA:SVM) rose 10% to 40.20p after the company published a definitive feasibility study for its Kasiya rutile and graphite project in Malawi, confirming a pre-tax net present value of $2.2 billion against initial capital expenditure of $727 million.
The study, completed with technical oversight from Rio Tinto Ltd (LSE:RIO, ASX:RIO, OTC:RTNTF), projects steady-state annual EBITDA of $476 million and free cash flow of $452 million over a 25-year mine life, with total revenue of $16.2 billion.